As part of its ongoing commitment to providing quality healthcare to Sub Saharan Africa, GE Healthcare presented its latest solutions during the ARCON conference held in Nigeria. The team is focused on bringing cutting edge technologies to the region to increase accessibility and provide clinicians with faster access to information and help increase the quality of care, particularly in the field of oncology.

In Nigeria, cancer leads to approximately 72,000 deaths every year. It is estimated that there are 102,000 new cases of cancer annually, with breast and cervical cancers as the two most common types, accounting for approximately 50 per cent of all cases. Given the disproportionate number of women impacted by these cancers, GE Healthcare’s focus on oncological diagnosis and care is a step forward in a key initiative for the country.

GE Healthcare has worked to support both public and the private sectors across the region, supporting the development of Nigeria’s healthcare infrastructure and bringing the latest solutions to the region, including anatomic imaging of CT and PET technologies, that allows for the visualization of cellular metabolism activity. This means that clinicians will be able to evaluate earlier whether a treatment is working, and tailor an appropriate therapy regimen according to patients’ unique needs, bringing an entirely new level of healthcare technology in the fight against cancer.

This technology combines images with high-quality, detailed information about the structure and function of the organs and tissues in the body, resulting in a comprehensive picture of what is going on inside the body. This has become an essential technology for clinicians to look at how certain diseases progress and develop.

One of GE Healthcare partners is Me Cure Healthcare Limited, a leading healthcare provider in Nigeria. Later this year, the partners will open a first-of-its-kind Positron Emission Tomography/Computed Tomography PET/CT system in West Africa.

The new centre highlights GE’s commitment to supporting the health sector in the region. The venture will help deliver enhanced diagnostic care, a key element in preventative measures and early diagnosis. Critically, the centre will seek to support patients in getting the right diagnosis and treatment closer to home. This is of particular importance in the context of the pandemic when travel abroad can be difficult and cost-prohibitive.

The Cyclotron technology that will be available at the centre is a large particle accelerator that spins protons as fast as 20 per cent of the speed of light (132 million mph). Agents are developed to light up a patient’s cancer or Parkinson’s disease markers during a diagnostic scan. With this technology, Me Cure aims to conduct PET/CT exams for over 3,000 patients a year. This will support the government’s goals of making screening services and early detection of cancer available for more Nigerians, and improving access to quality, cost-effective, and equitable diagnostic and treatment services for cancer care. 

Samir Udani, Chairman at Me cure Healthcare, said, “I am proud to be part of this project, as it will contribute to better healthcare for people across West Africa, and in Nigeria in particular. The strong will of the team allowed us to move forward with this partnership with GE Healthcare, which supports our vision in improving the diagnostic and treatment experience of our patients, to provide high quality and accessible clinical and outpatient services to the people of Nigeria.”

Eyong Ebai, General Manager of GE Healthcare in Sub-Saharan Africa, said, “Our purpose is to improve lives in moments that matter, and this is an example of partnering to help deliver sustainable and accessible precision care to all. The patient is the centre of everything we do and we are proud to continue providing technologies that can help detect cancer early, reducing overall mortality rates and improving quality of life. By providing our innovative PET/CT technologies in Nigeria, we are delivering on our commitment to make a positive impact in the communities in which we live.”

About GE Healthcare  

GE Healthcare is the $18 billion healthcare business of GE (NYSE: GE). As a leading global medical technology and digital solutions innovator, GE Healthcare enables clinicians to make faster, more informed decisions through intelligent devices, data analytics, applications and services, supported by its Edison intelligence platform. 

With over 100 years of healthcare industry experience and around 50,000 employees globally, the company operates at the centre of an ecosystem working toward precision health, digitizing healthcare, helping to drive productivity and improve outcomes for patients, providers, health systems and researchers around the world. 

 About Me Cure 

Me Cure Healthcare Limited is a family of 400 employees that was established in 2009 and is headquartered in Nigeria. The group started as a pharmaceutical company manufacturing prescription and TC medication and since have ventured into diagnostics, eye-care, Dental Care and cancer management. 

Me Cure saw the opportunity as a dearth in medical diagnostics and quickly offered reliable investigations for more than 2500 tests to now become a household name for imaging, pathology and cardiac-care services. During the past four years, we have launched seven healthcare diagnostic centres in Nigeria (including three public-private partnership centres signed with Abia and Ondo). We have also

endeavornigeria
endeavornigeria

Elsewhere on Ventures

Triangle arrow